CStone Pharmaceuticals (HKG:2616) said CEO, President of R&D and executive director Jianxin Yang bought 496,000 shares in the open market for more than HK$2.7 million from Sept. 17 to 22, according to a Thursday Hong Kong bourse filing.
Following the purchases, Yang's interest in CStone rose to about 5.31% of the company's issued share capital. He has bought a total of 14.21 million shares in the open market since becoming CEO in August 2022.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.